AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16595232 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 14
Study 16595232 — intervention group
Group type: COMPARATOR
Intervention: Acidified Tyrode's hatching
Number of subjects: 14
Study 14632720 — intervention group
Group type: COMPARATOR
Intervention: Insulin/gliclazide
Number of subjects: 80
Study 14632720 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/repaglinide
Number of subjects: 80
Study 10939691 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and isoflurane
Number of subjects: 854
Study 10939691 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and enflurane
Number of subjects: 854
Study 10939691 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA) with propofol
Number of subjects: 854
Study 10939691 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol
Number of subjects: 854
Study 10437193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupuncture, pilose antler essence injection to acupoints, and oral administration of Chinese materia medica
Number of subjects: 279
Study 8256404 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterless technique (no ureteral or urethral catheters)
Number of subjects: 34
Study 8256404 — intervention group
Group type: COMPARATOR
Intervention: Ureteral and urethral catheters
Number of subjects: 34
Study 3534849 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg/Hydrochlorothiazide 12.5 mg once daily (o.d.)
Number of subjects: 56
Study 3534849 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/Hydrochlorothiazide 25 mg once daily (o.d.)
Number of subjects: 56
Study 3534849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30048788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neurophysiological monitoring (IONM) change
Number of subjects: 79
Study 30048788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IONM change)
Number of subjects: 79
Study 30048788 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analysis for IONM change
Number of subjects: 79
Study 30048788 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outcomes related to IONM change
Number of subjects: 79
Study 27519180 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led group
Number of subjects: 680
Study 27519180 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led group
Number of subjects: 680
Study 27519180 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet version of the prevention program
Number of subjects: 680
Study 27519180 — intervention group
Group type: COMPARATOR
Intervention: Educational video
Number of subjects: 680
Study 25059854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg orally)
Number of subjects: 14
Study 25059854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22482373 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 8 mcg/kg (N8)
Number of subjects: 45
Study 22482373 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 4 mcg/kg (N4)
Number of subjects: 45
Study 22482373 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (SF)
Number of subjects: 45
Study 21490978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) and face mask therapy
Number of subjects: 33
Study 21490978 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class III subjects)
Number of subjects: 33
Study 17272491 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (500 mg/day)
Number of subjects: 55
Study 17272491 — intervention group
Group type: EXPERIMENTAL
Intervention: mixed tocopherols (500 mg/day)
Number of subjects: 55
Study 17272491 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 15655442 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort care (swaddled, held, and given 24% sucrose solution)
Number of subjects: 30
Study 15655442 — intervention group
Group type: COMPARATOR
Intervention: Control (examined while lying in their cribs)
Number of subjects: 30
Study 12142596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Closure (VAC)
Number of subjects: 28
Study 12142596 — intervention group
Group type: COMPARATOR
Intervention: Healthpoint System (HP)
Number of subjects: 28
Study 12142596 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 28
Study 12142596 — intervention group
Group type: COMPARATOR
Intervention: HP
Number of subjects: 28
Study 9932843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrosidase
Number of subjects: 28
Study 9932843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrosidase plus milk
Number of subjects: 28
Study 9932843 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of sacrosidase
Number of subjects: 28
Study 9932843 — intervention group
Group type: COMPARATOR
Intervention: Lower concentrations of sacrosidase
Number of subjects: 28
Study 9932843 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (no sacrosidase)
Number of subjects: 28
Study 7800307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone sulfate (DHAS) 200 mg intravenous in 20 mL of 5% dextrose
Number of subjects: 10
Study 7800307 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mL of 5% dextrose)
Number of subjects: 10
Study 2347955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg taken orally twice daily (7:00 AM and 7:00 PM) during the trial period.
Number of subjects: 12
Study 2347955 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (4 mg/kg) administered intravenously without ceftibuten treatment.
Number of subjects: 12
Study 659922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml intramuscularly (im) administered human diploid cell rabies virus vaccine
Number of subjects: 77
Study 659922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermally (id) administered human diploid cell rabies virus vaccine
Number of subjects: 77
Study 659922 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine administered by subcutaneous or id route
Number of subjects: 77
Study 31804433 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational program for oncology nurses
Number of subjects: 0
Study 31804433 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in recruitment strategies (adding incentives, shortening surveys, increasing reminders)
Number of subjects: 0
Study 31634441 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Position (KP)
Number of subjects: 44
Study 31634441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 27164220 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Theacrine (TeaCrine®)
Number of subjects: 24
Study 27164220 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Theacrine (TeaCrine®)
Number of subjects: 24
Study 27164220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 25179314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 43
Study 25179314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 22972745 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg + DMARDs
Number of subjects: 886
Study 22972745 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg + DMARDs
Number of subjects: 886
Study 22972745 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg monotherapy
Number of subjects: 886
Study 22972745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 886
Study 20478003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse follow-up
Number of subjects: 110
Study 20478003 — intervention group
Group type: COMPARATOR
Intervention: Surgeon follow-up
Number of subjects: 110
Study 19767814 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein mixture (9% sucrose solution + 3% whey protein isolate, 0.4 g.kg‐1 body mass.h‐1)
Number of subjects: 17
Study 19767814 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate alone (9% sucrose solution, 1.2 g.kg‐1 body mass.h‐1)
Number of subjects: 17
Study 17582067 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (11 mg/kg intramuscularly daily for 21 days)
Number of subjects: 667
Study 17582067 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (1 mg/kg intravenously every other day for 30 days)
Number of subjects: 667
Study 17582067 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin
Number of subjects: 667
Study 17582067 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 667
Study 15363822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazapril (force titrated to 5/40 mg)
Number of subjects: 6300
Study 15363822 — intervention group
Group type: COMPARATOR
Intervention: Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg)
Number of subjects: 6300
Study 11765671 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety committee regulations
Number of subjects: 3286
Study 11765671 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety program regulations
Number of subjects: 3286
Study 11765671 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance carrier loss control regulations
Number of subjects: 3286
Study 11765671 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting initiatives
Number of subjects: 3286
Study 9551418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate (38 mM) solution
Number of subjects: 18
Study 9551418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate (25 mM)/lactate (15 mM) solution
Number of subjects: 18
Study 9551418 — intervention group
Group type: COMPARATOR
Intervention: Control lactate (40 mM) solution
Number of subjects: 18
Study 7846213 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 + 50 mg)
Number of subjects: 0
Study 7846213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3214495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 100 mg
Number of subjects: 40
Study 3214495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 200 mg
Number of subjects: 40
Study 3214495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg
Number of subjects: 40
Study 3214495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 600 mg
Number of subjects: 40
Study 3214495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 800 mg
Number of subjects: 40
Study 3214495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30870203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 10
Study 30870203 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (sustained-release 12.5 mg)
Number of subjects: 10
Study 30870203 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine (30 mg IR) plus zolpidem (10 mg)
Number of subjects: 10
Study 30870203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29035169 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention for patients preparing for HCV treatment
Number of subjects: 154
Study 29035169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent abstinence from alcohol, drugs, and smoking
Number of subjects: 154
Study 29035169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent use of alcohol, drugs, and smoking
Number of subjects: 154
Study 29035169 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of abstinence after study entry for alcohol, drugs, and smoking
Number of subjects: 154
Study 27495186 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 gift card incentive
Number of subjects: 152
Study 27495186 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 152
Study 25698120 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-based nutritional intervention (50 g/day soy-protein-based nutritional supplement)
Number of subjects: 92
Study 25698120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study 23578528 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention
Number of subjects: 16329
Study 23578528 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 16329
Study 20806678 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials
Number of subjects: 170
Study 20806678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive seminars
Number of subjects: 170
Study 20806678 — intervention group
Group type: COMPARATOR
Intervention: Both educational strategies
Number of subjects: 170
Study 19139000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 50
Study 19139000 — intervention group
Group type: COMPARATOR
Intervention: Intensive inspection (standard colonoscopy)
Number of subjects: 50
Study 16206100 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sulfate combined with a 2-week course of lansoprazole, clarithromycin, and amoxicillin
Number of subjects: 219
Study 16206100 — intervention group
Group type: COMPARATOR
Intervention: Iron sulfate alone
Number of subjects: 219
Study 16206100 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-based quadruple therapy (re-treatment)
Number of subjects: 219
Study 12800480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (insulin infusion tailored to control blood glucose levels in the range 80-110 mg/dL)
Number of subjects: 1548
Study 12800480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 1548
Study 10235612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon retreatment at original dose (group A1: 234 MU, 11 patients; group B1: 468 MU, 10 patients)
Number of subjects: 42
Study 10235612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon retreatment at twice the original dose (group A2: 468 MU, 11 patients; group B2: 936 MU, 10 patients)
Number of subjects: 42
Study 10235612 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 42
Study 10235612 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete sustained responders
Number of subjects: 42
Study 10235612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the dose of interferon above that of the first cycle
Number of subjects: 42
Study 8729100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/d for 3 months)
Number of subjects: 35
Study 8729100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1898811 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 180 mg l/ml
Number of subjects: 64
Study 1898811 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg l/ml
Number of subjects: 64
Study 1898811 — intervention group
Group type: COMPARATOR
Intervention: barium
Number of subjects: 64
Study 6549746 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-sensitive enteric coated pancreatic enzyme preparation
Number of subjects: 6
Study 6549746 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreatic enzyme preparation
Number of subjects: 6
Study 30979342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural households
Number of subjects: 376
Study 30979342 — intervention group
Group type: COMPARATOR
Intervention: Urban households
Number of subjects: 376
Study 29300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured verbal instruction plus a leaflet
Number of subjects: 60
Study 29300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured verbal instruction
Number of subjects: 60
Study 29300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet alone
Number of subjects: 60
Study 29300292 — intervention group
Group type: COMPARATOR
Intervention: Usual care (unstructured verbal counseling)
Number of subjects: 60
Study 26979765 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Unicondylar Knee Arthroplasty (MUKA)
Number of subjects: 32
Study 26979765 — intervention group
Group type: COMPARATOR
Intervention: Minimally Invasive Total Knee Arthroplasty (TKA)
Number of subjects: 32
Study 25074878 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Number of subjects: 329
Study 25074878 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 329
Study 25074878 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity burden score
Number of subjects: 329
Study 25074878 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 329
Study 22230921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral SAL (6 mg)
Number of subjects: 8
Study 22230921 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral SAL (12 mg day(‐1) for 3 weeks)
Number of subjects: 8
Study 22230921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gelatin)
Number of subjects: 8
Study 20845112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management plus Expressive Supportive Therapy (CBSM+)
Number of subjects: 451
Study 20845112 — intervention group
Group type: COMPARATOR
Intervention: Individual informational intervention
Number of subjects: 451
Study 17643995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g) administered 15 min before the end of surgery and every 6h for 72 h
Number of subjects: 113
Study 17643995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 113
Study 17643995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 17101319 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human ghrelin (0.33 mug/kg)
Number of subjects: 38
Study 17101319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 38
Study 12794781 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 60
Study 12794781 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 60
Study 12794781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib and Celecoxib
Number of subjects: 60
Study 12794781 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors with COX-2 NSAIDs
Number of subjects: 60
Study 11056128 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 15 microg daily
Number of subjects: 240
Study 11056128 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 50 microg daily
Number of subjects: 240
Study 11056128 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 100 microg daily
Number of subjects: 240
Study 11056128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9366786 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded-exercise test (G-test)
Number of subjects: 52
Study 9366786 — intervention group
Group type: COMPARATOR
Intervention: Constant-load test (C-test)
Number of subjects: 52
Study 1328579 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial milk formula containing 1% bovine milk immunoglobulin concentrate from hyperimmunized cows
Number of subjects: 232
Study 1328579 — intervention group
Group type: COMPARATOR
Intervention: Commercial milk formula (control)
Number of subjects: 232
Study 2412793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency sinusoidal whole body vibration (0.3 m/sec2, rms)
Number of subjects: 30
Study 2412793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency random whole body vibration (0.3 m/sec2, rms)
Number of subjects: 30
Study 2412793 — intervention group
Group type: COMPARATOR
Intervention: Pauses without exposure to vibration
Number of subjects: 30
Study 31421157 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib
Number of subjects: 424
Study 31421157 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 424
Study 31421157 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (per protocol population)
Number of subjects: 424
Study 31421157 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone (per protocol population)
Number of subjects: 424
Study 31421157 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup without cirrhosis)
Number of subjects: 424
Study 31421157 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup cirrhosis of non-alcoholic aetiology)
Number of subjects: 424
Study 31421157 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup patients ≤65 years old)
Number of subjects: 424
Study 31421157 — intervention group
Group type: COMPARATOR
Intervention: SIRT only
Number of subjects: 424
Study 30586005 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (1/100 mg)
Number of subjects: 1994
Study 30586005 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (0.5/100 mg)
Number of subjects: 1994
Study 30586005 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (0.5/50 mg)
Number of subjects: 1994
Study 30586005 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (0.25/50 mg)
Number of subjects: 1994
Study 30586005 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (all doses)
Number of subjects: 1994
Study 30586005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1994
Study 26859081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and mitoxantrone (HAM)
Number of subjects: 3375
Study 26859081 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine, daunorubicin and 6-thioguanine (TAD)
Number of subjects: 3375
Study 26859081 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 3375
Study 26859081 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 3375
Study 26859081 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplant
Number of subjects: 3375
Study 26859081 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 3375
Study 24534204 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg
Number of subjects: 85